Leonhardt and Genovese File Patent for Bioelectric Control of CXCL5 a Potential Protector Against Artery Occlusion and Cancer Tumor Growth

Salt Lake City, Utah and Los Angeles, CA – December 19th, 2017 (PRBUZZ) — Leonhardt’s Launchpads, an organ regeneration innovation/startup accelerator, focused on developing novel therapeutics for the treatment of organ degeneration today announced that it has filed a new patent application for the controlled up or down regulation of CXCL5 expression. CXCL5 is a protein known from previous pre-clinical studies to have a role in preventing artery occlusion and cancer tumor growth as well as many other potential useful therapeutic applications including the treatment of arthritis. This patent will be sub-licensed exclusively organ by organ to up to 27 unique organ regeneration focused startups within the Leonhardt’s Launchpads innovation accelerators in Utah and California including CancerCell, PancreaCell, DentaCell Accelerator, LiverCell, BioLeonhardt and VascuStim.


The protein encoded by this gene, CXCL5 is a small cytokine belonging to the CXC chemokine family that is also known as epithelial-derived neutrophil-activating peptide 78 (ENA-78). It is produced following stimulation of cells with the inflammatory cytokines interleukin-1or tumor necrosis factor-alpha.  Expression of CXCL5 has also been observed in eosinophils, and can be inhibited with the type II interferon IFN-γ. This chemokine stimulates the chemotaxis of neutrophils possessing angiogenic properties. It elicits these effects by interacting with the cell surface chemokine receptor CXCR2. The gene for CXCL5 is encoded on four exons and is located on human chromosome 4 amongst several other CXC chemokine genes. CXCL5 has been implicated in connective tissue remodeling. CXCL5 has been also described to regulate neutrophil homeostasis.

Clinical significance

CXCL5 plays a role in reducing sensitivity to sunburn pain in some subjects, and is a “potential target which can be utilized to understand more about pain in other inflammatory conditions like arthritis and cystitis.”. CXCL5 is well known to have chemotactic and activating functions on neutrophil, mainly during acute inflammatory responses. However CXCL5 expression is also higher in artherosclerosis (a chronic inflammatory condition) but is not associated with neutrophil infiltration. Instead CXCL5 has a protective role in atherosclerosis by directly controlling macrophage foam cell formation.
“We targeted the discovery search for the precise bioelectric signals and sequence for triggering CXCL5 expression control up and down on demand from tissues more than 7 years ago and we are delighted to finally hit on it.  This adds to our building library of over a nineteen bioelectric stimulation signals for promoting organ regeneration and cancer tumor treatment. We believe this combined with our programmable micro-infusion pump and fifteen component organ regeneration composition puts our team in a leadership position to in the near future to potentially help patients with degenerating and diseased organs to recover.” Dr. Jorge Genovese, VP of Bioelectric Regeneration Research at Leonhardt’s  Launchpads

The Leonhardt-Genovese team working in collaboration with component suppliers has developed both wireless non-invasive and implantable wire lead based means to get their bioelectric signals intended for regeneration and healing or cancer recovery to organs.

The bioelectric stimulation signals for controlling up or down regulation of CXCL5 are licensed exclusively organ by organ without additional fees or royalties to organ specific portfolio startups within the Leonhardt’s Launchpads innovation and startup accelerator(s) as per the terms of accelerator participation.

CXCL5 reported potential properties for organ regeneration and recovery including cancer tumor treatment…

> CXCL5 control has been identified as a potential treatment for liver cancer – LiverCell.
> CXCL5 control has been identified as a potential treatment for prostrate cancer – MyoStim ED.
> CXCL5 control has been been identified as a potential treatment for atherosclerosis of arteries – BioLeonhardt and VascuStim.
> CXCL5 control has been identified as potential treatment for colorectal cancer – CancerCell.
> CXCL5 control has been identified as a potential treatment for pancreatic cancer – PancreaCell.
> CXCL5 control has been identified as potential treatment for pneumonia, acute respiratory distress syndrome and other lung disorders – RegenaLung
> CXCL5 control has been identified as a potential treatment for arthritis – InStim
> CXCL5 as an important mediator of the inflammatory pain that occurs after sunburn – SkinCell Stimulator by MyoStim Skin.
> CXCL5-secreting pulmonary epithelial cells drive destructive neutrophilic inflammation in tuberculosis – RegenaLung
> CXCL5 control has been identified as a potential treatment for nerve regeneration – CerebraCell and VascuStim.
> CXCL5 control has been identified as a potential treatment for brain recovery after injury by helping to manage inflammation – CerebraCell
> CXCL5 control has been identified to have a role in diabetic foot and leg ulcer wound healing – VascuStim
> CXCL5 control has been identified as potentially having a role in increasing responders to knee stem cell therapy due to inflammation reduction – VascuStim and InStim
> CXCL5 control has been identified as potential treatment for periodontitis – DentaCell Accelerator
> CXCL5 control has been identified as potential treatment in neuropathic pain management – CerebraCell

“The CXCL5 protein was found in previous pre-clinical studies to be a key cytokine in potentially reducing risk of heart attacks, strokes and limb amputations due to atherosclerosis and resulting artery occlusion.  Control of CXCL5 expression has also been suggested from data gathered in numerous studies as a possible means to stop cancer tumor growth.  We are delighted to be adding bioelectric up or down regulation control of CXCL5 to our armamentarium of technologies for organ regeneration and recovery.” states Howard Leonhardt, co-Inventor, Executive Chairman & CEO of Leonhardt’s Launchpads

“CXCL5 is one of the most potent cytokines known to reduce risk of arterial occlusion that is a primary cause of heart attacks and stroke as well as lower limb ischemia.  Numerous studies have demonstrated that controlled downregulation of CXCL5 can be antii-angiogenic and thus help starve cancer tumors of blood supply. We are proud to have extended our portfolio of bioelectrical stimulation signals to include CXCL5. We are embarking upon well controlled translational research studies to prove our combination therapy out for regenerative repair and recovery of a number of organs including those that may be ravaged with cancer tumors.” states Dr. Leslie Miller, Chief Medical Officer of Leonhardt’s Launchpads


(1) CXCL5 limits macrophage foam cell formation in atherosclerosis – https://www.ncbi.nlm.nih.gov/pubmed/23376791

(2) Clinical Evidence of a Protective Role for CXCL5 in Coronary Artery Disease Progression in the Elderly – http://www.fasebj.org/content/30/1_Supplement/1177.17

(3) CXCL5, a promoter of cell proliferation, migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer – http://www.sciencedirect.com/science/article/pii/S0959804911009956

(4) Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer- https://www.ncbi.nlm.nih.gov/pubmed/21356384

“Elevated levels of CXCL5 are found in patients with fast growing cancer tumors.  A number of small animal studies have confirmed that down regulation or inhibition of CXCL5 can serve to help reduce or stop cancer tumor growth especially in combination with other cancer therapies.  We look forward to exploring for the first time the real time monitoring and controlled regulation of CXCL5 with specific bioelectric signals as described in these patent claims pending.  Control of the expression of this specific cytokine can be incorporated into a overall real time inflammation monitoring and control protocol with other bioelectric signals directed towards inflammation control and organ recovery.”  stated Dr. Santosh Kesari, Director of Research, Pacific Neurosciences Institute and John Wayne Cancer Institute, Santa Monica, California and Chief Advisor for CerebraCell and CancerCell two startups in the Leonhardt’s Launchpads innovation and startup accelerator.

CXCL5 biological processes include…

> Postive regulation of leukocyte chemotaxis.
> Positive regulation of cell proliferation
> Inflammatory response.
> G-protein coupled receptor signaling pathway.
> Response to lipopolysacchraride.
> Signal transduction.
> Cell-cell signaling
> Immune response.
> Chemokine-mediated signaling pathway.
> Cell chemotaxis.
> Neutrophil mediated immunity.

“Adipose derived stem cells release CXCL5 which may be on the contributing elements to their potency in organ healing”  Dr. Leslie Miller, Chief Medical Officer further stated.  Reference:   Adipose Tissue-Derived Stem Cells Secrete CXCL5 Cytokine with Neurotrophic Effects on Cavernous Nerve Regeneration https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3176296/

The Leonhardt’s Launchpads team announced earlier this year…
1.  License agreement for IP estate for bioelectric cancer tumor treatment from Neuro Code Tech Holdings.
2.  Filing of new patents pending for multiple modality bioelectric cancer tumor treatment.
3.  Launch of InStim startup focused on real time bioelectric inflammation monitoring and management.
4.  Launch of PressureStim and licensing of patents for bioelectric blood pressure control.
5.  $1 million raised for startup Second Heart Assist, Inc.
6.  License agreement with Caltech for IP estate related to circulatory assist support.
7.  Launch of VascuStim clinical research program for diabetic ulcer treatment.

See https://leonhardtventures.com/news/ to links to previous news stories.

About Leonhardt’s  Launchpads:
Operated by Cal-X Stars Business Accelerator, Inc. DBA Leonhardt’s Launchpads is the innovation and startup accelerator arm of Leonhardt Ventures and inventor Howard J. Leonhardt.  The five year accelerator is incubating 27 regenerative medtech and 3 regenerative economy startups and licensable technology platforms (LTPs). The accelerator has affiliated offices and labs in Santa Monica, Petaluma, Playa Vista, Torrance and Pasadena, California and in Salt Lake City, Utah.  Life science incubator/accelerator operations began in 2008 at the University of Northern California Science & Technology Innovation Center (UNC STIC) in Santa Rosa, California under Leonhardt Ventures (Leonhardt Vineyards LLC DBA Leonhardt Ventures founded in 2005). In 2013 the organization was incorporated and moved its headquarters to Santa Monica, California and in 2017 expanded to Playa Vista, California where its primary headquarters are now.

About Leonhardt’s Launchpads Utah, Inc.:   Founded in November 2015 in Salt Lake City, Utah, just off the campus of the University of Utah, is an organ regeneration focused innovation and startup accelerator. The company has lab space at the USTAR BioInnovations Gateway Utah facility at 2500 S. State Street, Salt Lake City, Utah and employs 5 biomedical engineers and biologists at this time and has recruited a half dozen local Utah based advisors.

About Leonhardt Ventures (Leonhardt Vineyards LLC DBA Leonhardt Ventures):  Founded in 1982 as a sole proprietorship is the patent holding vehicle and venture capital arm of inventor Howard J. Leonhardt (formed into Califiornia LLC in 2005). In the 1980’s Leonhardt patented and developed a market leading cardiovascular balloon catheter, in the 1990’s the leading stent graft system for endovascular aortic aneurysm repair and one of the first percutaneous heart valves and biological pacemakers. Since 2000 the focus has been on organ regeneration technologies with a combination of bioelectric signaling and repeat delivery of mixed stem cell + growth factor based compositions.  More recently Leonhardt has added a strong estate of IP related to bioelectric cancer tumor treatment, real time inflammation and blood pressure management as well as a “brain saving helmet” designed for cerebral stroke patients.  Leonhardt has over 21 U.S. Patents with over 100 issued patent claims and dozens more pending.  Leonhardt inventions have been used to treat more than 400,000 patients to date.

About BioLeonhardt:  BioLeonhardt LTP founded in 2013 is the flagship technology platform of Leonhardt Ventures, Leonhardt’s Launchpads by Cal-X Stars Business Accelerator, Inc., and Leonhardt’s Launchpads Utah, Inc. focused on heart regeneration. BioLeonhardt developed a combination three component system for heart regeneration comprised of (1) a bioelectric stimulator controlling release of regeneration promoting proteins including stem cell homing factors, (2) an implantable, programmable and re-fillable micro infusion pump and (3) a fifteen component stem cell based heart regeneration composition.

Cautionary Note Regarding Forward-Looking Statements:

Statements in this press release regarding the efficacy, safety, and intended utilization of Leonhardt’s Launchpads product candidates; the conduct, size, timing and results of discovery efforts and clinical trials; scope, duration, validity and enforceability of intellectual property rights; plans regarding regulatory filings, future research and clinical trials; plans regarding current and future collaborative activities and the ownership of commercial rights; future royalty streams, and any other statements about Cal-X Stars Business Accelerator, Inc. DBA  Leonhardt’s  Launchpads, Leonhardt Vineyards LLC DBA Leonhardt Ventures, or Leonhardt’s Launchpads Utah, Inc. management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact our business are set forth in our 506D part C Cal-X Stars Business Accelerator, Inc. private placement memorandum originally filed in 2013 and updated via our Annual Reports. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we assume no obligation to update these forward-looking statements.

Web Sites:

VascuStim – www.vascustim.com 
Leonhardt Ventures www.lventuresnestg.wpenginepowered.com – this site includes links to all portfolio startups.
BioLeonhardt LTP www.bioleonhardt.com

DentaCell Accelerator www.dentacellaccelerator.com 

Cal-X Stars Business Accelerator, Inc http://calxstars.com/what-we-do/ includes links to videos of platform innovations.
Leonhardt’s Launchpads Utah, Inc. https://leonhardtventures.com/leonhardts-launchpads-utah/

Leonhardt’s Launchpads by Cal-X Stars Business Accelerator, Inc, 12655 W Jefferson Blvd, Los Angeles, CA 90066

Leonhardt’s Launchpads Utah, Inc. 370 S, 300 E, Salt Lake City, UT 84111
Research Lab @ 2500 S State St. #224, Salt Lake City, UT 84111

Leonhardt Ventures (Leonhardt Vineyards LLC DBA Leonhardt Ventures), 12760 Millennium Drive, Unit 213, Playa Vista, CA  90094